Evi Lianidou
YOU?
Author Swipe
View article: Supplementary Figure S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Figure S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Figure 1. Diagram showing patient disposition.
View article: Supplementary Methods S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Methods S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Methods 1
View article: Supplementary Table S6 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S6 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 6: Comparisons of the probabilities of patients that are CTC positive at baseline being a CTC responder (i.e., switching from CTC positive at baseline to CTC negative at first follow-up) between HER2-positive/hormone re…
View article: Data from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Data from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Purpose:The aim of PREDICT was to confirm clinical validity and the potential for clinical utility of serial circulating tumor cell (CTC) enumeration in patients with metastatic breast cancer, focusing on its prognostic value in different …
View article: Supplementary Table S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 1. Clinical trials, multicenter studies, and institutions/centers that provided data sets from MBC patients for the pooled analysis.
View article: Supplementary Figure S3 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Figure S3 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Figure 3: Kaplan-Meier plots of overall survival (OS) according to CTC status at baseline for HER2-positive/hormone receptor-positive tumors(A, B) and HER2-positive/hormone receptor-negative tumors(C, D). Survival time is giv…
View article: Supplementary Table S7 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S7 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 7. Median overall survival (OS) and hazard ratios for the CTC change groups as categorized based on the ≥5 CTC cutoff for CTC positivity (reference group neg/neg) for patients with hormone receptor-positive/HER2-negativ…
View article: Supplementary Table S8 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S8 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 8. Median overall survival (OS) and hazard ratios for the CTC change groups as categorized based on the ≥5 CTC cutoff for CTC positivity (reference group neg/neg) for patients with HER2-positive/ hormone receptor-positi…
View article: Supplementary Table S2 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S2 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 2. Absolute and relative frequencies of CTC change groups and percentage of CTC responders (as categorized according to the ≥1 CTC or ≥5 CTC cutoff for CTC positivity) overall, according to tumor subtypes and according …
View article: Supplementary Figure S4 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Figure S4 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Figure 4. Kaplan-Meier plot of overall survival according to change in CTC status from baseline to first follow-up (cutoff for CTC positivity ≥1 CTC). (A) HER2-positive/hormone receptor-positive tumors; (B) HER2-positive/horm…
View article: Supplementary Figure S2 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Figure S2 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Figure 2: Kaplan-Meier plots of overall survival (OS) according to CTC status at baseline for a cutoff for CTC positivity ≥1 CTC (A, B, C) and a cutoff for CTC positivity ≥5 CTCs (D, E, F). Survival time is given as time sinc…
View article: Supplementary Table S5 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S5 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 5: Comparisons of the probabilities of patients that are CTC positive at baseline being a CTC responder (i.e., switching from CTC positive at baseline to CTC negative at first follow-up) among tumor subtypes (hormone re…
View article: Supplementary Table S9 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S9 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 9. Median overall survival (OS) and hazard ratios for the CTC change groups as categorized based on the ≥5 CTC cutoff for CTC positivity (reference group neg/neg) for patients that received chemotherapy-based or endocri…
View article: Supplementary Table S3 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S3 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 3: Comparisons of the probabilities of being CTC positive among tumor subtypes (hormone receptor-positive/HER2-negative, HER2-positive, triple-negative) according to time point of CTC assessment (baseline, first follow-…
View article: Supplementary Table S4 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S4 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 4: Comparisons of the probabilities of being CTC positive betweenHER2- positive/hormone receptor-positive and HER2-positive/hormone receptor-negative tumors according to time point of CTC assessment (baseline, first fol…
View article: Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Purpose: The aim of PREDICT was to confirm clinical validity and the potential for clinical utility of serial circulating tumor cell (CTC) enumeration in patients with metastatic breast cancer, focusing on its prognostic value in different…
View article: Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers
Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers Open
The PD1/PD-L1 axis plays an important immunosuppressive role during the T-cell-mediated immune response, which is essential for the physiological homeostasis of the immune system. The biology of the immunological microenvironment is extrem…
View article: Detection rate for <scp> <i>ESR1</i> </scp> mutations is higher in circulating‐tumor‐cell‐derived genomic <scp>DNA</scp> than in paired plasma cell‐free <scp>DNA</scp> samples as revealed by <scp>ddPCR</scp>
Detection rate for <span> <i>ESR1</i> </span> mutations is higher in circulating‐tumor‐cell‐derived genomic <span>DNA</span> than in paired plasma cell‐free <span>DNA</span> samples as revealed by <span>ddPCR</span> Open
Plasma cell‐free DNA (cfDNA) analysis to track estrogen receptor 1 ( ESR1 ) mutations is highly beneficial for the identification of tumor molecular dynamics and the improvement of personalized treatments for patients with metastatic breas…
View article: Direct comparison of an ultrasensitive real-time PCR assay with droplet digital PCR for the detection of PIK3CA hotspot mutations in primary tumors, plasma cell-free DNA and paired CTC-derived gDNAs
Direct comparison of an ultrasensitive real-time PCR assay with droplet digital PCR for the detection of PIK3CA hotspot mutations in primary tumors, plasma cell-free DNA and paired CTC-derived gDNAs Open
Introduction Detection of PIK3CA mutations in primary tumors and liquid biopsy samples is of increasing importance for treatment decisions and therapy resistance in many types of cancer. The aim of the present study was to directly compare…
View article: NALCN Promoter Methylation as a Biomarker for Metastatic Risk in a Cohort of Non-Small Cell Lung Cancer Patients
NALCN Promoter Methylation as a Biomarker for Metastatic Risk in a Cohort of Non-Small Cell Lung Cancer Patients Open
Liquid biopsy enables real-time monitoring of tumor development and response to therapy through the analysis of CTCs and ctDNA. NALCN is a sodium leak channel that is frequently involved in tumor evolution and immunity and acts as a tumor …
View article: Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers
Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers Open
The PD1/PD-L1 axis plays an important immunosuppressive role during the T cell mediated immune response, which is essential for the physiological homeostasis of the immune system. The biology of the immunological microenvironment is extrem…
View article: Profiling Plasma Extracellular Vesicle Metabotypes and miRNAs: An Unobserved Clue for Predicting Relapse in Patients with Early-Stage NSCLC
Profiling Plasma Extracellular Vesicle Metabotypes and miRNAs: An Unobserved Clue for Predicting Relapse in Patients with Early-Stage NSCLC Open
Background and Objective: Lung cancer, the second most prevalent cancer globally, poses significant challenges in early detection and prognostic assessment. Despite advancements in targeted therapies and immunotherapy, the timely identific…
View article: Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment
Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment Open
Background The heterogeneous and complex genetic landscape of NSCLC impacts the clinical outcomes of patients who will eventually develop resistance to osimertinib. Liquid biopsy (LB) analysis as a minimally invasive approach is a key step…
View article: Development and validation of a multi-marker liquid bead array assay for the simultaneous detection of PIK3CA and ESR1 hotspot mutations in single circulating tumor cells (CTCs)
Development and validation of a multi-marker liquid bead array assay for the simultaneous detection of PIK3CA and ESR1 hotspot mutations in single circulating tumor cells (CTCs) Open
The developed novel multi-marker liquid bead array assay for the simultaneous detection of PIK3CA and ESR1 hotspot mutations in single CTCs is highly specific, highly sensitive, high-throughput, and sample-, cost-, and time-saving. This mu…
View article: Pyrimidine-Dependent UV-Mediated Cross-Linking Magnifies Minor Genetic or Epigenetic Changes in Clinical Samples
Pyrimidine-Dependent UV-Mediated Cross-Linking Magnifies Minor Genetic or Epigenetic Changes in Clinical Samples Open
Background Detection of minor DNA allele alterations is becoming increasingly important for early detection and monitoring of cancer. We describe a new method that uses ultraviolet light to eliminate wild-type DNA alleles and enables impro…
View article: Comprehensive Analysis of CXCR4, JUNB, and PD-L1 Expression in Circulating Tumor Cells (CTCs) from Prostate Cancer Patients
Comprehensive Analysis of CXCR4, JUNB, and PD-L1 Expression in Circulating Tumor Cells (CTCs) from Prostate Cancer Patients Open
CXCR4, JUNB and PD-L1 are implicated in cancer progression and metastasis. The current study investigated these biomarkers in CTCs isolated from metastatic prostate cancer (mPCa) patients at the RNA and protein levels. CTCs were isolated f…
View article: Multiplex detection of ten ESR1 mutations and AKT1 E17K in breast cancer using digital PCR
Multiplex detection of ten ESR1 mutations and AKT1 E17K in breast cancer using digital PCR Open
The Stilla 12plex ESR1-AKT 6-color Crystal Digital PCR® assay is multiplex, highly sensitive and robust and can be used in liquid biopsy.
View article: Supplementary Figure 2 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Supplementary Figure 2 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer Open
Supplementary Figure 2. Differentially expressed signatures in Responders relative to no-Responders. Response is based on physical examination, pathology or imaging. Responders had higher scores in Inflammatory Chemokines and Exhausted CD8…